A Herpes Simplex Virus Recombinant That Exhibits a Single-Chain Antibody to HER2eu Enters Cells through the Mammary Tumor Receptor Independently of the gD Receptors

摘要

The human epidermal growth factor receptor 2euregulin (HER2eu) receptor is overexpressed in highly malignant mammary and ovarian tumors and correlates with a poor prognosis. It is a target for therapy; humanized monoclonal antibodies to HER2 have led to increased survival of patients with HER2eu-positive breast cancer. As a first step in the design of an oncolytic herpes simplex virus able to selectively infect HER2eu-positive cells, we constructed two recombinants, R-LM11 and R-LM11L, that carry a single-chain antibody (scFv) against HER2 inserted at residue 24 of gD. The inserts were 247 or 256 amino acids long, and the size of the gD ectodomain was almost doubled by the insertion. We report the following. R-LM11 and R-LM11L infected derivatives of receptor-negative J or CHO cells that expressed HER2eu as the sole receptor. Entry was dependent on HER2eu, since it was inhibited in a dose-dependent manner by monoclonal antibodies to HER2eu and by a soluble form of the receptor. The scFv insertion in gD disrupted the ability of the virus to enter cells through HVEM but maintained the ability to enter through nectin1. This report provides proof of principle that gD can tolerate fusion to a heterologous protein almost as large as the gD ectodomain itself without loss of profusion activity. Because the number of scFv's to a variety of receptors is continually increasing, this report makes possible the specific targeting of herpes simplex virus to a large collection of cell surface molecules for both oncolytic activity and visualization of tumor cells.